adrenal tumours
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: patients with adrenal tumours who have provided written informed consent
Exclusion criteria
Exclusion criteria: no exclusion criteria are defined
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Collection of biomaterial will be performed to provide the basis for the identification of novel biomarkers to improve individualized therapeutic regiments. Specifically, the following parameters will be taken into account: 1. Prognostic markers: An increasing number of adrenal masses are detected incidentally during imaging (*adrenal incidentalomas*), but the assessment of the malignant potential of these tumours by imaging procedures is difficult. Even in patients operated on, both adrenocortical carcinoma and malignant pheochromocytoma can often not be definitely distinguished from benign adrenal tumours based on histomorphological features alone, and within both entities a phenotypic range exists that impairs consistent prognostic classification. Reliable and sensitive screening tools for early detection and risk stratification of adrenal cancers are currently lacking, which makes the development of such tools a clinical priority. Similarly, benign adrenal tumours can be associated with significant morbidity and mortality due to their endocrine activity. Definition of patient subgroups with increased cardiovascular risk profile would enable initiation of close follow-up and justify more aggressive treatment. Newly applied genomic techniques including expression analysis, microRNA profiling, methylation pattern, chromosomal gains and losses, proteome techniques and exon sequencing will refine a set of markers that identify subgroups of tumours with defined biological behaviour. Lymphocytic DNA will be utilized for comparison of genetic markers identified during mutation analysis. Validation of identified marker genes will be performed by immunohistochemical approaches on paraffin embedded and frozen tumour material. Furthermore, functional characterization of fresh tumor specimen will be included in in vitro (primary cell culture) and in vivo (xenotransplantation model) assays. Secreted markers will be assessed by metabolome techniques i | — |
Secondary
| Measure | Time frame |
|---|---|
| no applicable | — |
Countries
Netherlands
Outcome results
None listed